Study on Protein Receptor’s Role in IBD Supports Decision to Develop Blocking Therapy, OSE Says

Study on Protein Receptor’s Role in IBD Supports Decision to Develop Blocking Therapy, OSE Says
A study that OSE Immunotherapeutics conducted on the role that a protein receptor plays in bowel disease supports its development of a treatment that blocks the receptor, the company reports. It designed OSE-127 (Effi-7) to help inflammatory bowel disease patients who fail to respond to treatments that suppress their immune system. OSE-127 blocks the interleukin-7 receptor. OSE presented the study's finding at the 11th European Workshop on Immune Mediated Inflammatory Diseases in Paushuis-Utrecht, the Netherlands, in mid-December. The title of the presentation was "Interleukin-7 receptor pathway controls human T cell homing to the gut and predicts response to anti-TNFα in patients with inflammatory bowel disease." The discovery sheds light on why preclinical-trial studies showed that OSE-127 works. The studies demontrasted that it prevents immune T-cells from reaching an inflamed colon, where they can do more damage. Blocking the T-cells from reaching the colon prevents the destruction of mucus that the gut needs to protect itself. Previous studies have linked a protein known as interleukin-7, or IL-7, with a variety of autoimmune diseases, including IBD. An autoimmune disease is one in which the immune system attacks healthy tissue instead of invaders. IL-7 is an important immune cell regulator. When inflammed tissue produces IL-7, T-cells go to the site of the inflammation to attack the protein. The T-cells then activate other immune cells, aggravating the infla
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *